Marquette University offers master’s in nursing option for professionals looking to change career paths
Pleasant Prairie will be location for new nursing simulation lab
MILWAUKEE — Marquette University will offer a unique program for professionals with non-nursing degrees to earn an accelerated master’s in nursing degree in as few as 18 months.
The expansion of Marquette’s Master of Science in Nursing Second Degree Direct Entry for Non-Nurses program (DE MSN) allows students to earn a master’s degree through a combination of online coursework and hands-on labs and in-hospital clinical rotations.
The Marquette program will have a student learning center and nursing simulation lab located in Pleasant Prairie, Wisconsin. The lab is expected to open in fall 2016; Marquette is currently accepting applications for the program. To learn more about applying visit mastersnursing.marquette.edu.
“Marquette and the College of Nursing are excited to launch this new option as an extension of our already established graduate nursing programs,” said Dr. Maureen O’Brien, associate dean. “To be able to offer a DE MSN for greater numbers of students with non-nursing degrees allows us to be the difference for our students and community.”
The program provides more accessibility to students by offering online coursework and providing two additional start dates each year, O’Brien added. It is scheduled to begin August 2016; a second class will start in January 2017.
“At Marquette, our goal is to provide a program that fits the lifestyle of individuals who are dedicated to changing careers,” said Angela Becerra-Chvilicek, DE MSN site director. “This higher degree prepares graduates with the necessary leadership and clinical skillset to excel both professionally and financially in the health care industry.”
To learn more, visit mastersnursing.marquette.edu or call (866) 891-8438.
Mentioned in This Press Release
Recent Press Releases by Marquette University
Troy leads a billion-dollar health system that is dedicated to children and employs nearly 5,000 people throughout the state.
Pudner has managed political campaigns for almost three decades.
The investment will finance key clinical trials of the company’s most promising compound targeting neuropsychiatric disorders.